Biohaven Ltd. (BHVN)
(Delayed Data from NYSE)
$48.66 USD
-0.38 (-0.77%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $48.65 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$48.66 USD
-0.38 (-0.77%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $48.65 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Zacks News
Texas Hospital Administers Cerner's (CERN) Millenium System
by Zacks Equity Research
Cerner's (CERN) EHR will provide comprehensive care to RHCD and improve patient engagement through a new online portal.
Here's Why You Should Invest in Fresenius Medical Right Now
by Zacks Equity Research
Fresenius Medical (FMS) receives a boost from solid guidance, higher geographical revenues and strategic acquisitions.
Why Abeona Therapeutics (ABEO) Could Be Positioned for a Slump
by Zacks Equity Research
Abeona Therapeutics (ABEO) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
Stryker Loses 7.6% in a Month: What's Weighing It Down?
by Zacks Equity Research
Stryker's (SYK) declining margins and demand for healthcare products raise concern.
Weakness Seen in Exelixis (EXEL) Estimates: Should You Stay Away?
by Zacks Equity Research
Exelixis (EXEL) has witnessed a significant price decline in the past four weeks, and has seen negative earnings estimate revisions for the current quarter and year.
Implied Volatility Surging for Biohaven Pharmaceutical (BHVN) Stock Options
by Zacks Equity Research
Investors in Biohaven Pharmaceutical (BHVN) need to pay close attention to the stock based on moves in the options market lately.